Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: A randomised, open-label, phase 2 study

The Lancet Oncology

Volumn 16, Issue 4, 2015, Pages 406-416

  Kawai, Akira ^a   Araki, Nobuhito ^b   Sugiura, Hideshi ^c   Ueda, Takafumi ^d   Yonemoto, Tsukasa ^e   Takahashi, Mitsuru ^f   Morioka, Hideo ^g   Hiraga, Hiroaki ^h   Hiruma, Toru ⁱ   Kunisada, Toshiyuki ^j   Matsumine, Akihiko ^k   Tanase, Takanori ^l   Hasegawa, Tadashi ^m   Takahashi, Shunji ⁿ  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f SHIZUOKA CANCER CENTER   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h HOKKAIDO CANCER CENTER   (Japan)

ⁱ KANAGAWA CANCER CENTER   (Japan)

^j OKAYAMA UNIVERSITY   (Japan)

^k MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l TAIHO PHARMACEUTICAL CO LTD   (Japan)

^m SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ CANCER INSTITUTE HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; DEXAMETHASONE; TETRAHYDROISOQUINOLINE DERIVATIVE; TRABECTEDIN;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; JAPAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; TREATMENT OUTCOME;

ADULT; DEXAMETHASONE; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SARCOMA; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84930588472     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70098-7     Document Type: Article

References (31)

1. Clark MA, Fisher C, Judson I, Thomas JM Soft-tissue sarcomas in adults. N Engl J Med 2005, 353:701-711.
2. Saanna GAI, Bovée J, Hornick J, Lazar A A review of the WHO classification of tumours of soft tissue and bone (accessed Aug 20, 2014). http://sarcomahelp.org/reviews/who-classification-sarcomas.html.
3. Mertens F, Antonescu CR, Hohenberger P, et al. Translocation-related sarcomas. Semin Oncol 2009, 36:312-323.
4. NCCN. Clinical practice guidelines in oncology. Soft tissue sarcoma, version 2. 2014.
5. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 3(suppl 3):iii102-iii112. ESMO/European Sarcoma Network Working Group.
6. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001, 37:870-877.
7. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007, 25:3144-3150.
8. Sharma S, Takyar S, Manson SC, Powell S, Penel N Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC Cancer 2013, 13:385.
9. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188-4196.
10. Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
11. Poindessous V, Koeppel F, Raymond E, Comisso M, Waters SJ, Larsen AK Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res 2003, 9:2817-2825.
12. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999, 10:1233-1240.
13. D'Incalci M, Galmarini CM A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010, 9:2157-2163.
14. Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011, 13:145-153.
15. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009, 8:449-457.
16. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007, 8:595-602.
17. Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer 2012, 48:3036-3044.
18. Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 2014, 50:1137-1147.
19. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prioranthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188-4196.
20. Ueda T, Kakunaga S, Ando M, et al. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Invest New Drugs 2014, 32:691-699.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
22. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
23. Rosing H, Hillebrand MJ, Jimeno JM, et al. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 1998, 33:1134-1140.
24. Van Glabbeke M, Verweij J, Judson I, Nielsen OS Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549.
25. Miura Y, Keira Y, Ogino J, et al. Detection of specific genetic abnormalities by fluorescence in situ hybridization in soft tissue tumors. Pathol Int 2012, 62:16-27.
26. Antonescu CR The role of genetic testing in soft tissue sarcoma. Histopathology 2006, 48:13-21.
27. VOTRIENT®: prescribing information GlaxoSmithKline, (accessed Nov 31, 2014). http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022465s018lbl.pdf.
28. Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012, 23:771-776.
29. Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007, 25:2122-2126.
30. Le Cesne A 13 years of trabectedin, 5 years of Yondelis: what have we learnt?. Expert Rev Anticancer Ther 2013, 13:11-19.
31. Martin-Liberal J, Judson I Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Expert Opin Drug Saf 2013, 12:905-911.